Rikke Fredslund Andersen

Medicine & Life Sciences

1. Circulating Tumor DNA 100%
2. Colorectal Neoplasms 84%
3. Cell-Free Nucleic Acids 68%
4. Biomarkers 48%
5. DNA 39%
6. Mutation 31%
7. Single Nucleotide Polymorphism 30%
8. Neoplasms 30%
9. MicroRNAs 30%
10. Ovarian Neoplasms 29%
11. Drug Therapy 29%
12. Rectal Neoplasms 27%
13. Bevacizumab 26%
14. Homeobox Genes 24%
15. Methylation 24%
16. Survival 24%
17. Progression-Free Survival 23%
18. Irinotecan 21%
19. Ovarian Epithelial Carcinoma 21%
20. Vascular Endothelial Growth Factor A 20%
21. Chemoradiotherapy 19%
22. Polymerase Chain Reaction 19%
23. Lung Neoplasms 18%
24. Non-Small Cell Lung Carcinoma 17%
25. Therapeutics 16%
26. delta tocotrienol 16%
27. Genes 14%
28. Circulating MicroRNA 13%
29. Capecitabine 13%
30. Genotype 13%
31. Biliary Tract Neoplasms 12%
32. Breast Neoplasms 11%
33. ErbB Receptors 11%
34. Response Evaluation Criteria in Solid Tumors 11%
35. gemcitabine 10%
36. Epidermal Growth Factor 9%
37. Neuropeptide Y 9%
38. Poly(ADP-ribose) Polymerase Inhibitors 9%
39. Liquid Biopsy 8%
40. Natural Killer Cells 8%
41. Oxaliplatin 8%
42. Colonic Neoplasms 8%
43. Cetuximab 8%
44. Serum 8%
45. Gene Amplification 7%
46. Complement C3d 7%
47. Vascular Endothelial Growth Factor Receptor-2 7%
48. Alleles 7%
49. Intracellular Signaling Peptides and Proteins 7%
50. regorafenib 7%